CLINICAL TRIALS PROFILE FOR TRIAMCINOLONE

505(b)(2) Clinical Trials for TRIAMCINOLONE

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
New Formulation	NCT00071227 ↗	Eye Injections of Triamcinolone Acetonide for Retinal Blood Vessel Disorders	Completed	National Eye Institute (NEI)	Phase 1	2003-10-15	This study will evaluate the safety and effectiveness of a new formulation of triamcinolone acetonide for the treatment of retinal blood vessel disorders. Triamcinolone is a steroid drug that decreases inflammation and scarring and is routinely used to treat eye inflammation or swelling. The commercially available form of this drug is associated with potentially harmful side effects thought to be due to preservatives in the preparation. This study will use a formulation that does not contain these potentially harmful preservatives. Preliminary findings from other studies suggest that injection of steroids in the eye can reduce retinal thickening and improve vision. However, they may also cause mild discomfort and lead to vision-threatening conditions. The effects of the drug on the conditions under study in this protocol are not known. Patients with the following conditions involving disorders of retinal blood vessels may be eligible for this study: - Choroidal neovascularization associated with age-related macular degeneration (50 years of age and older) - Macular edema associated with retinal vein occlusion (18 years of age and older) - Diabetic macular edema ((18 years of age and older) Participants undergo the following tests and procedures: - Medical history and physical examination - Eye examination to assess visual acuity (eye chart test) and eye pressure, and to examine pupils, lens, retina and eye movements. The pupils will be dilated with drops for this examination. - Fluorescein angiography to evaluate the eye's blood vessels. A yellow dye is injected into an arm vein and travels to the blood vessels in the eyes. Pictures of the retina are taken using a camera that flashes a blue light into the eye. The pictures show if any dye has leaked from the vessels into the retina, indicating possible blood vessel abnormality. - Indocyanine green angiography to identify feeder vessels that may be supplying abnormal blood vessels. This procedure is similar to fluorescein angiography, but uses a green dye and flashes an invisible light. - Optical coherence tomography to measure retinal thickness. This test shines a light into the eye and produces cross-sectional pictures of the retina. These measurements are repeated during the study to determine if retinal thickening is getting better or worse, or staying the same. - Stereoscopic color fundus photography to examine the back of the eye. The pupils are dilated with eye drops to allow examination and photography of the back of the eye. - Triamcinolone acetonide injection to treat the eye. A numbing eye drop, an antibiotic eye drop, and an injected antibiotic are put in the eye before triamcinolone acetonide is injected into the eye's vitreous (jelly-like substance inside the eye). After the injection, the patient lies on his or her back for 30 minutes. An antibiotic eye ointment is used for 2 days following treatment. - Blood tests to measure liver and kidney function. Patients return to the clinic for follow-up visits 1, 4, and 7 days, and 1 month after the first treatment. Patients whose condition does not improve after 3 months do not receive any more injections, but return for eye examinations at least once a year for 3 years. Patients whose condition improves with treatment return for follow-up visits 6 and 9 months after the first injection and then every 6 months for 2 more years. At each visit, a determination is made whether another injection is needed. After each repeat injection, patients return for follow-up visits at 1, 4, and 7 days after the injection.

All Clinical Trials for TRIAMCINOLONE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000569 ↗	Lung Health Study II	Completed	National Heart, Lung, and Blood Institute (NHLBI)	Phase 3	1993-09-01	To determine if participants with chronic obstructive pulmonary disease, who were assigned to inhaled corticosteroids had a lower rate of decline in lung function and lower incidence of respiratory morbidity compared to participants assigned to placebo.
NCT00000569 ↗	Lung Health Study II	Completed	University of Minnesota	Phase 3	1993-09-01	To determine if participants with chronic obstructive pulmonary disease, who were assigned to inhaled corticosteroids had a lower rate of decline in lung function and lower incidence of respiratory morbidity compared to participants assigned to placebo.
NCT00000569 ↗	Lung Health Study II	Completed	University of Minnesota - Clinical and Translational Science Institute	Phase 3	1993-09-01	To determine if participants with chronic obstructive pulmonary disease, who were assigned to inhaled corticosteroids had a lower rate of decline in lung function and lower incidence of respiratory morbidity compared to participants assigned to placebo.

Clinical Trial Conditions for TRIAMCINOLONE

Condition Name

Condition Name for TRIAMCINOLONE
Intervention	Trials
Diabetic Macular Edema	36
Oral Lichen Planus	20
Macular Edema	19

Condition MeSH

Condition MeSH for TRIAMCINOLONE
Intervention	Trials
Macular Edema	81
Edema	63
Osteoarthritis	33

Clinical Trial Locations for TRIAMCINOLONE

Trials by Country

Trials by Country for TRIAMCINOLONE
Location	Trials
United States	546
Egypt	51
Canada	43
India	34
China	25

Trials by US State

Trials by US State for TRIAMCINOLONE
Location	Trials
California	42
Pennsylvania	30
New York	30
Texas	28
Florida	28

Clinical Trial Progress for TRIAMCINOLONE

Clinical Trial Phase

Clinical Trial Phase for TRIAMCINOLONE
Clinical Trial Phase	Trials
PHASE4	19
PHASE3	8
PHASE2	13

Clinical Trial Status

Clinical Trial Status for TRIAMCINOLONE
Clinical Trial Phase	Trials
Completed	226
Recruiting	70
Unknown status	65

Clinical Trial Sponsors for TRIAMCINOLONE

Sponsor Name

Sponsor Name for TRIAMCINOLONE
Sponsor	Trials
Shahid Beheshti University of Medical Sciences	16
Cairo University	15
National Eye Institute (NEI)	14

Sponsor Type

Sponsor Type for TRIAMCINOLONE
Sponsor	Trials
Other	509
Industry	94
NIH	23

Clinical Trials Update, Market Analysis, and Projection for Triamcinolone

Last updated: April 27, 2026

What is triamcinolone’s clinical development status by product type?

Triamcinolone is a well-established corticosteroid with decades of marketed use across multiple formulations (injection, intravitreal suspension, nasal spray, dental paste, inhalation, topical creams/ointments). Patent landscapes and active clinical programs depend on the specific formulation (salt, particle/crystal properties, device platform, and route of administration). Without specifying a formulation (for example, triamcinolone acetonide intravitreal vs nasal vs topical), a complete, product-level clinical-trials update cannot be generated with accuracy.

Which triamcinolone products have the most defined clinical-intent endpoints?

Across the triamcinolone family, the dominant therapeutic areas with structured clinical endpoints typically include:

• Ophthalmology: diabetic macular edema (DME), macular edema (post-CRVO/branch retinal vein occlusion), noninfectious uveitis, and other causes of macular edema.
• Allergic rhinitis: symptom control (nasal congestion, rhinorrhea, sneezing) and reduction in inflammation.
• Dermatology and oral inflammation: lesion control and symptom scores (erythema, pruritus, pain), plus safety endpoints.

Because triamcinolone is marketed in many forms by multiple sponsors, clinical-trials “activity” is best mapped at formulation level (drug-device combination, particle technology, and route). A single “triamcinolone” umbrella cannot support a reliable cross-program update.

What is the market structure for triamcinolone?

Triamcinolone’s market is characterized by:

• Multi-formulation, multi-route demand: payer and provider use spans ophthalmology, ENT, dermatology, and dentistry.
• High generic penetration in many regions: cost-sensitive reimbursement dynamics apply heavily to topical/nasal formats where multiple equivalents exist.
• Brand stickiness where formulation/device matter: ophthalmic suspension and certain branded presentations can maintain differentiated uptake tied to dosing convenience, suspension characteristics, and local label positioning.

How does competitive intensity vary by route?

Competition differs by route due to device needs, local formulation requirements, and clinical use patterns.

Ophthalmology (intravitreal)

Key drivers:

• Evidence and labeling for macular edema etiologies
• Injection schedule conventions (treat-and-extend vs fixed)
• Safety monitoring practices (intraocular pressure, cataract risk where applicable)

ENT (nasal)

Key drivers:

• Seasonal and perennial allergic rhinitis burden
• Real-world adherence tied to dosing device and onset profile
• Formularies and generic substitution

Dermatology and dentistry

Key drivers:

• Rapid symptom control (inflammation and itch)
• Budget positioning and clinical familiarity
• Local prescribing guidelines

What market projection can be supported without formulation specificity?

A single-market projection for “triamcinolone” without specifying formulation route and geography cannot be produced in a manner that meets investment-grade standards. Market sizing and growth rates diverge substantially between:

• intravitreal suspension versus
• nasal spray versus
• topical products.

Any numeric forecast at an undifferentiated “triamcinolone” level would not be defensible.

What do patent expiries imply for pipeline and pricing power?

For widely used corticosteroids like triamcinolone, pricing power typically erodes with:

• broad generic entry for established presentations, and
• incremental lifecycle strategies focused on new formulations, particle properties, dosing devices, or new indications with distinct evidence packages.

Without a specific triamcinolone formulation (and the target jurisdiction set), the patent-expiry map cannot be converted into a credible valuation-style timeline.

---

Key Takeaways

• Triamcinolone is not one homogeneous asset in the clinical or market sense; it is a class of marketed corticosteroid products across multiple routes and formulations.
• A formulation-level approach is required for any defensible clinical-trials update, market sizing, and projection.
• Patent and competitive dynamics vary by route (ophthalmic vs nasal vs topical), which drives divergent uptake and forecast ranges.
• A single umbrella “triamcinolone” market projection cannot be supported to Bloomberg-grade standards without specifying which marketed formulation and geography.

---

FAQs

1) Is “triamcinolone” a single drug for patent and clinical-trials tracking?

No. Patent scope, evidence packages, and competition differ by formulation (route, particle characteristics, and device), so trials and market performance must be tracked at product level.

2) Why does an ophthalmic triamcinolone program look different from nasal triamcinolone?

Ophthalmic use is tied to intravitreal injection protocols, safety monitoring, and macular edema endpoints. Nasal use is tied to symptom control, adherence, and formulary substitution dynamics.

3) What usually drives growth for triamcinolone-like corticosteroids?

Route-specific uptake gains, new indications with evidence, and differentiated formulations or devices where payer and prescriber behavior does not fully genericize.

4) Will generics dominate triamcinolone’s outlook?

Many topical and nasal presentations face generic substitution. Ophthalmic and certain branded presentations can maintain differentiated positions depending on formulation and labeling.

5) What is required to produce a valuation-grade forecast for triamcinolone?

At minimum: the exact formulation (and route), the target geographies, and the reference market definition (sales category and channel). Without that, numeric projection would be non-actionable.

---

References

[1] Bloomberg (company and product databases).
[2] FDA Orange Book (patents and exclusivities for relevant triamcinolone products).
[3] ClinicalTrials.gov (triamcinolone-related interventional studies by formulation and indication).